Allogene Therapeutics (ALLO) Operating Expenses (2018 - 2026)

Allogene Therapeutics has disclosed Operating Expenses across 9 years of filings, most recently posting $46.1 million for Q1 2026.

• Operating Expenses for Q1 2026 came in at $46.1 million, down 29.3% year-over-year; the trailing twelve-month figure through Mar 2026 was $190.2 million (down 29.26% YoY), and the FY2025 annual result was $209.3 million, down 23.39% from the prior year.
• Operating Expenses came in at $46.1 million for Q1 2026 at Allogene Therapeutics, up from $42.4 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $99.1 million in Q1 2023 to a low of $42.4 million in Q4 2025.
• The 5-year median for Operating Expenses is $71.4 million (2024), against an average of $70.1 million.
• Across the five-year window, Operating Expenses soared 30.4% in 2022 and sank 37.44% in 2025, its largest moves.
• Allogene Therapeutics' Operating Expenses stood at $96.4 million in 2022, then declined by 11.71% to $85.1 million in 2023, then dropped by 28.94% to $60.5 million in 2024, then declined by 29.9% to $42.4 million in 2025, then grew by 8.7% to $46.1 million in 2026.
• The last three Operating Expenses figures came in at $46.1 million (Q1 2026), $42.4 million (Q4 2025), and $44.9 million (Q3 2025), per Business Quant data.